- Isracann Biosciences (IPOT) has closed the first tranche of a non-brokered private placement for gross proceeds of $233,980
- The company issued 4,679,600 units at $0.05 per unit
- Each unit consists of one common share and one share purchase warrant
- Isracann is a cannabis focused producer and product developer
- Isracann Biosciences Inc. (IPOT) opened trading at C$0.05
Isracann Biosciences (IPOT) has closed the first tranche of a non-brokered private placement.
The company issued 4,679,600 units at $0.05 per unit for gross proceeds of $233,980. Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to acquire one additional share for 48 months.
Net proceeds will be used to fund product development and for general operations.
All securities issued will be subject to a statutory four-month hold period ending on December 3, 2022.
Isracann is a cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm.
Isracann Biosciences Inc. (IPOT) opened trading at C$0.05.
